Annemarie Hanekamp

Oncology

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.